Savvy Trades and Investments

[RNsidersbuying]

NBIO .10 - several officers accumulating:

Nascent CFO Lowell Holden stated, "I believe the Company has continued to be undervalued and is now positioned to add significant value. The IND clearance by the FDA, along with the pending clinical trials, gives me confidence in its growth."

https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Officers-Convert-Liability-to-Stock-in-the-Company?id=267054